APA (7th ed.) Citation

Han, J., Zhong, Y., Zhong, J., Zeng, W., & Sun, L. (2025). First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis. PLoS ONE, 20(6), 1. https://doi.org/10.1371/journal.pone.0325808

Chicago Style (17th ed.) Citation

Han, Jing-Wen, Yu Zhong, Jin Zhong, Wen-Jing Zeng, and Li-Jun Sun. "First-line Toripalimab Plus Chemotherapy Versus Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma: A Cost-effectiveness Analysis." PLoS ONE 20, no. 6 (2025): 1. https://doi.org/10.1371/journal.pone.0325808.

MLA (9th ed.) Citation

Han, Jing-Wen, et al. "First-line Toripalimab Plus Chemotherapy Versus Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma: A Cost-effectiveness Analysis." PLoS ONE, vol. 20, no. 6, 2025, p. 1, https://doi.org/10.1371/journal.pone.0325808.